By Jessica Achtsam
On March 31, 2015, Orthofix International N.V. announced it entered into an 18-month option agreement to acquire eNeura, Inc. Orthofix’s website states that the focus of the company is on “improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide.” In May 2014, eNeura received FDA 501(k) clearance for a portable, non-invasive Transcranial Magnetic Stimulation (TMS) device for the treatment of migraine headache. According to the press release, eNeura’s “SpringTMS™ is the first medical device available to patients in the United States for the acute treatment of pain associated with migraine headache with aura.” The eNeura website states that “The SpringTMS™ is the only non-drug therapy clinically proven to effectively stop or reduce migraine at the first sign of pain.”
According to the press release, “Spring TMS™ is a prescription-only device that utilizes single-pulse Transcranial Magnetic Stimulation (sTMS) to induce very mild electrical currents that can depolarize neurons in the brain. This process is thought to interrupt the abnormal hyperactivity associated with migraine.” The press release states that to treat the pain of a migraine headache, the Spring TMS™ device is placed on the back of the head and generates a focused magnetic pulse.
The press release notes that Orthofix agreed to pay eNeura $15 million to assist in commercialization of Spring TMS in the US and Europe, and Orthofix has the option to pay $65 million to complete the purchase.
